-
Sichuan Huiyu Pharmaceutical Wins Marketing Approvals in Italy, Portugal, Saudi Arabia
•
China-based Sichuan Huiyu Pharmaceutical Co., Ltd (SHA: 688553) has announced its its subsidiaries Seacross Pharma (Europe) and Seacross Pharmaceuticals Ltd. receiving a series of marketing approvals for its products in Italy, Portugal, and Saudi Arabia. The approved products include valproate concentrated solution, zoledronic acid, teicoplanin, and plerixafor. Valproate Concentrated SolutionValproate,…
-
Sichuan Huiyu Pharmaceutical’s HY-2003 Approved for Clinical Trials by China’s NMPA
•
Sichuan Huiyu Pharmaceutical Co., Ltd (SHA: 688553), a China-based pharmaceutical company, has announced that it has received clinical trial approval from the National Medical Products Administration (NMPA) for its Category 2.2 modified drug, HY-2003. This drug is designed to improve moderate to severe contour protrusion caused by subcutaneous fat accumulation…
-
Sichuan Huiyu Pharmaceutical’s HYP-6589 Receives NMPA Approval for Solid Tumor Clinical Trial
•
Sichuan Huiyu Pharmaceutical Co., Ltd (SHA: 688553), a China-based pharmaceutical company, has announced that it has received clinical trial approval from the National Medical Products Administration (NMPA) for its Category 1 chemical drug, HYP-6589, which targets advanced solid tumors. HYP-6589’s Mechanism of ActionHYP-6589 is an in-house developed SOS1 small molecule…
-
Sichuan Huiyu Pharmaceutical’s Chairman Ding Zhao Faces CSRC Investigation for Short-Term Stock Trading
•
Sichuan Huiyu Pharmaceutical Co., Ltd (SHA: 688553), a Chinese pharmaceutical company, has disclosed that its Chairman and General Manager, Ding Zhao, is under investigation by the China Securities Regulatory Commission (CSRC) for suspected short-term trading of the company’s shares. The matter is a personal inquiry into Mr. Ding Zhao and…
-
Sichuan Huiyu’s HY07121 Antifungal Protein Earns NMPA Review for Clinical Trials
•
Sichuan Huiyu Pharmaceutical Co., Ltd (SHA: 688553), a Chinese biopharmaceutical company, has announced that the National Medical Products Administration (NMPA) has accepted its clinical trial filing for HY07121, an innovative antibody fusion protein targeting PD-1, TIGIT, and IL-15 for the treatment of advanced solid tumors. The drug candidate, classified as…
-
China’s Sichuan Huiyu Pharmaceutical Halts Generic Cytosar Launch Following Strategy Review
•
Sichuan Huiyu Pharmaceutical Co., Ltd (SHA: 688553), a pharmaceutical company based in China, has announced the withdrawal of its market filing for a generic version of Cytosar (cytarabine), a drug originally developed by US firm Viatris. The decision to withdraw the filing, which was initially submitted in September 2022, is…
-
TYK Medicines Secures Nearly RMB 200 Million in Series D Financing Led by Sichuan Huiyu Pharmaceutical
•
Shanghai-based TYK Medicines (HKG: 2410) has successfully completed a Series D financing round, raising nearly RMB 200 million (approximately USD 28 million). The round was led by Sichuan Huiyu Pharmaceutical Co., Ltd. (SHA: 688553), with additional investments from CICC Capital, Changxing Financial Holding, and the Huzhou Talent Fund. Founded in…
-
Sichuan Huiyu Pharmaceutical’s HYP2090PTSA Gains NMPA Approval for KRAS G12C Solid Tumors
•
Sichuan Huiyu Pharmaceutical Co., Ltd (SHA: 688553), a China-based pharmaceutical company, has announced that it has received clinical trial approval from the National Medical Products Administration (NMPA) for its investigational drug HYP2090PTSA. This small molecule KRAS G12C/PI3K inhibitor is intended for the treatment of advanced solid tumors with KRAS G12C…
-
Sichuan Huiyu Pharmaceutical’s Plerixafor Gains Marketing Approval from Italian Medicines Agency
•
Sichuan Huiyu Pharmaceutical Co., Ltd (SHA: 688553), a China-based pharmaceutical company, has announced that it has received marketing approval for its plerixafor from the Italian Medicines Agency (AIFA). The drug is approved for use in combination with granulocyte colony stimulating factor (G-CSF) to mobilize hematopoietic stem cells (HSCs) into the…
-
Sichuan Huiyu Pharmaceutical’s KRAS G12C Drug HYP-2090PTSA Accepted for NMPA Review
•
Sichuan Huiyu Pharmaceutical Co., Ltd (SHA: 688553), a China-based pharmaceutical company, has announced that the National Medical Products Administration (NMPA) has accepted a clinical trial filing for its Category 1 investigational drug, HYP-2090PTSA. This small molecule drug candidate targets KRAS G12C and PI3K and is under review for potential use…
